Kymera Therapeutics Presented Preclinical Data Showcasing Impact of IRAK4 Degrader KT-474 on Immune and Skin Cells at the Society for Investigative Dermatology Annual Meeting
WATERTOWN, Mass., May 20, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, presented data demonstrating that the clinical stage selective IRAK4 degrader KT-474 degrades IRAK4 and inhibits cytokine production in different immune and skin cell types at the Society of Investigative Dermatology (SID) Annual Meeting 2022, taking place from May 18 - 21, 2022 in Portland, Oregon.
The poster presentation highlights the broad impact of KT-474 across multiple disease-relevant cell types and supports the continued development of IRAK4 degraders in patients with HS, AD and other IL-1R/TLR-driven autoimmune diseases of the skin where IRAK4 plays a central role in the pathogenesis of inflammation.
“We have found that KT-474 effectively degrades IRAK4 in both circulating immune cells and resident skin cells such as keratinocytes and fibroblasts, albeit interestingly with different kinetics,” said Anthony Slavin, Vice President, Immunology. “These findings are aligned with what we have observed in our Phase 1 clinical study of KT-474 in healthy volunteers, which showed near complete IRAK4 degradation in peripheral blood mononuclear cells and skin following multiple daily doses and robust ex vivo inhibition of multiple disease-relevant cytokines.”
Poster at SID Annual Meeting:
Kymera is colaborating with Sanofi on the development of degrader candidates targeting IRAK4, including KT-474 (SAR444656), for indications outside of oncology and immuno-oncology.
About Kymera Therapeutics
Founded in 2016, Kymera is headquartered in Watertown, Mass. Kymera has been named a “Fierce 15” biotechnology company by Fierce Biotech and has been recognized by the Boston Business Journal as one of Boston’s “Best Places to Work.” For more information about our people, science, and pipeline, please visit www.kymeratx.com or follow us on Twitter or LinkedIn.
Cautionary Note Regarding Forward-Looking Statements